FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
MAPS’ Policy Values Over the last three years since MAPS published our Considerations For the Regulation and Decriminalization of Psychedelic Substances statement, multiple policy approaches to psychedelics …
Today, the White House released a statement that President Joe Biden “will grant a pardon to all people convicted of simple marijuana possession under federal law” and “urged governors to take similar …
Senate Bill 519 would have decriminalized the personal possession of certain psychedelic substances, legalized life-saving public health interventions, and studied future approaches to increasing use of …
United States Sentencing Commission, which establishes and advises Congress on federal sentencing guidelines, reaches first quorum in 3 years and a full slate for first time since 2014 Delayed appointments …
Yesterday, a letter from the U.S. Department of Health and Human Services was made public describing the Food and Drug Administration’s “anticipated approval…within approximately 24 months” of …
Psychedelic Fundamentals is the initial offering in the new MAPS Digital Learning program introducing learners to the most important aspects of psychedelic history, research, uses, and harm reduction The …
Historic Curated “Cartography of the Mind: A Curated NFT Sale” Auction is the First Time MAPS has Raised Money Using NFTs Beeple’s PILGRIMAGEPrice Realized: $252,000 Digital art, inspired by personal …
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated …
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board …
Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …